{"id": "article-24900_0", "title": "Medroxyprogesterone -- Continuing Education Activity", "content": "Medroxyprogesterone\u00a0is used to prevent pregnancy in females of reproductive potential and for women experiencing amenorrhea due to hormonal imbalance, excluding organic pathologies such as fibroids and uterine cancer. Additionally,\u00a0medroxyprogesterone is used for abnormal uterine bleeding due to ovulatory dysfunction, prevention of endometrial hyperplasia, pain related to endometriosis, and in patients with inoperable, recurrent, and/or metastatic endometrial carcinoma as adjunctive and/or palliative treatment. Medroxyprogesterone, a progestin, is similar in structure to naturally occurring progesterone. The mechanism of action of progestin involves binding the progesterone receptor in the hypothalamus, female reproductive tract, and pituitary and inhibiting the secretion of gonadotropin-releasing hormone (GnRH).", "contents": "Medroxyprogesterone -- Continuing Education Activity. Medroxyprogesterone\u00a0is used to prevent pregnancy in females of reproductive potential and for women experiencing amenorrhea due to hormonal imbalance, excluding organic pathologies such as fibroids and uterine cancer. Additionally,\u00a0medroxyprogesterone is used for abnormal uterine bleeding due to ovulatory dysfunction, prevention of endometrial hyperplasia, pain related to endometriosis, and in patients with inoperable, recurrent, and/or metastatic endometrial carcinoma as adjunctive and/or palliative treatment. Medroxyprogesterone, a progestin, is similar in structure to naturally occurring progesterone. The mechanism of action of progestin involves binding the progesterone receptor in the hypothalamus, female reproductive tract, and pituitary and inhibiting the secretion of gonadotropin-releasing hormone (GnRH)."}
{"id": "article-24900_1", "title": "Medroxyprogesterone -- Continuing Education Activity", "content": "This\u00a0activity highlights medroxyprogesterone as contraception to prevent pregnancy\u00a0and discusses the mechanism of action, adverse effects, monitoring, and contraindications for medroxyprogesterone, as well as the importance of\u00a0regularly monitoring patients for\u00a0adverse effects. An interprofessional team comprising primary care, ob/gyn, or related specialties might provide the best recommendations.", "contents": "Medroxyprogesterone -- Continuing Education Activity. This\u00a0activity highlights medroxyprogesterone as contraception to prevent pregnancy\u00a0and discusses the mechanism of action, adverse effects, monitoring, and contraindications for medroxyprogesterone, as well as the importance of\u00a0regularly monitoring patients for\u00a0adverse effects. An interprofessional team comprising primary care, ob/gyn, or related specialties might provide the best recommendations."}
{"id": "article-24900_2", "title": "Medroxyprogesterone -- Continuing Education Activity", "content": "Objectives: Identify appropriate indications for medroxyprogesterone, including contraception, hormone replacement therapy, and management of abnormal uterine bleeding. Screen patients for contraindications and potential risks associated with medroxyprogesterone use, such as thromboembolic disorders and hormone-sensitive cancers. Assess patient response to medroxyprogesterone treatment and monitor for adverse effects or complications. Implement\u00a0effective interprofessional collaboration regarding\u00a0the benefits, risks, potential adverse effects, and administration of medroxyprogesterone, ensuring informed decision-making. Access free multiple choice questions on this topic.", "contents": "Medroxyprogesterone -- Continuing Education Activity. Objectives: Identify appropriate indications for medroxyprogesterone, including contraception, hormone replacement therapy, and management of abnormal uterine bleeding. Screen patients for contraindications and potential risks associated with medroxyprogesterone use, such as thromboembolic disorders and hormone-sensitive cancers. Assess patient response to medroxyprogesterone treatment and monitor for adverse effects or complications. Implement\u00a0effective interprofessional collaboration regarding\u00a0the benefits, risks, potential adverse effects, and administration of medroxyprogesterone, ensuring informed decision-making. Access free multiple choice questions on this topic."}
{"id": "article-24900_3", "title": "Medroxyprogesterone -- Indications", "content": "Medroxyprogesterone, a synthetic progestin, is commonly prescribed for\u00a0the medical conditions described below.", "contents": "Medroxyprogesterone -- Indications. Medroxyprogesterone, a synthetic progestin, is commonly prescribed for\u00a0the medical conditions described below."}
{"id": "article-24900_4", "title": "Medroxyprogesterone -- Indications -- Labeled Indications", "content": "Contraception (104 mg/0.65 mL and 150 mg/mL injection): Medroxyprogesterone acetate (MPA) injection is used to prevent pregnancy in females of reproductive potential. [1] Amenorrhea, secondary (tablet): Women experiencing amenorrhea due to hormonal imbalance and not because of organic pathologies such as fibroids and uterine cancer. [2] Abnormal uterine bleeding (tablet): The American College of Obstetricians and Gynecologists (ACOG) recommends\u00a0medroxyprogesterone\u00a0for women experiencing abnormal bleeding due to\u00a0ovulatory dysfunction; use is not advised for organic pathologies such as fibroids and uterine cancer. [3] Endometrial hyperplasia prevention (tablet): Medroxyprogesterone\u00a0is administered to non-hysterectomized postmenopausal patients receiving a daily oral dose of estrogen of 0.625 mg. [4]", "contents": "Medroxyprogesterone -- Indications -- Labeled Indications. Contraception (104 mg/0.65 mL and 150 mg/mL injection): Medroxyprogesterone acetate (MPA) injection is used to prevent pregnancy in females of reproductive potential. [1] Amenorrhea, secondary (tablet): Women experiencing amenorrhea due to hormonal imbalance and not because of organic pathologies such as fibroids and uterine cancer. [2] Abnormal uterine bleeding (tablet): The American College of Obstetricians and Gynecologists (ACOG) recommends\u00a0medroxyprogesterone\u00a0for women experiencing abnormal bleeding due to\u00a0ovulatory dysfunction; use is not advised for organic pathologies such as fibroids and uterine cancer. [3] Endometrial hyperplasia prevention (tablet): Medroxyprogesterone\u00a0is administered to non-hysterectomized postmenopausal patients receiving a daily oral dose of estrogen of 0.625 mg. [4]"}
{"id": "article-24900_5", "title": "Medroxyprogesterone -- Indications", "content": "Endometrial carcinoma (400 mg/mL injection or 100 mg tablet): In patients with inoperable, recurrent, and/or metastatic endometrial carcinoma,\u00a0medroxyprogesterone acetate is used as adjunctive and/or palliative treatment. [4] Endometriosis (104 mg/0.65 mL injection): Used in patients experiencing pain related to endometriosis. [5]", "contents": "Medroxyprogesterone -- Indications. Endometrial carcinoma (400 mg/mL injection or 100 mg tablet): In patients with inoperable, recurrent, and/or metastatic endometrial carcinoma,\u00a0medroxyprogesterone acetate is used as adjunctive and/or palliative treatment. [4] Endometriosis (104 mg/0.65 mL injection): Used in patients experiencing pain related to endometriosis. [5]"}
{"id": "article-24900_6", "title": "Medroxyprogesterone -- Indications -- Off-Label Indications", "content": "Acute abnormal uterine bleeding [6] Endometrial hyperplasia [7] [8] Hot flashes [9] Paraphilia/hypersexuality [10]", "contents": "Medroxyprogesterone -- Indications -- Off-Label Indications. Acute abnormal uterine bleeding [6] Endometrial hyperplasia [7] [8] Hot flashes [9] Paraphilia/hypersexuality [10]"}
{"id": "article-24900_7", "title": "Medroxyprogesterone -- Indications", "content": "Some research indicates that women with sickle-cell disease are considered good candidates for\u00a0medroxyprogesterone; the drug\u00a0has been shown to reduce sickle-cell pain in women. [11] Medroxyprogesterone\u00a0is also considered to\u00a0cause\u00a0a decreased incidence of seizures in women with seizure disorders. [2] Due to its association with respiratory centers, medroxyprogesterone has been used to treat patients with COPD, hypercapnia, sleep apnea, and Pickwickian syndrome. [12]", "contents": "Medroxyprogesterone -- Indications. Some research indicates that women with sickle-cell disease are considered good candidates for\u00a0medroxyprogesterone; the drug\u00a0has been shown to reduce sickle-cell pain in women. [11] Medroxyprogesterone\u00a0is also considered to\u00a0cause\u00a0a decreased incidence of seizures in women with seizure disorders. [2] Due to its association with respiratory centers, medroxyprogesterone has been used to treat patients with COPD, hypercapnia, sleep apnea, and Pickwickian syndrome. [12]"}
{"id": "article-24900_8", "title": "Medroxyprogesterone -- Mechanism of Action", "content": "Medroxyprogesterone is similar in structure to naturally occurring progesterone. The mechanism of action of progestin involves binding the progesterone receptor in the hypothalamus, female reproductive tract, and pituitary and inhibiting the secretion of gonadotropin-releasing hormone (GnRH). [1] By decreasing the frequency of release of GnRH,\u00a0medroxyprogesterone blunts the midcycle LH surge and prevents follicular maturation and ovulation. Medroxyprogesterone changes a proliferative endometrium to secretory endometrium, making implantation difficult. Finally,\u00a0medroxyprogesterone also impairs sperm migration into the uterus by increasing the viscosity of the cervical mucus. [1]", "contents": "Medroxyprogesterone -- Mechanism of Action. Medroxyprogesterone is similar in structure to naturally occurring progesterone. The mechanism of action of progestin involves binding the progesterone receptor in the hypothalamus, female reproductive tract, and pituitary and inhibiting the secretion of gonadotropin-releasing hormone (GnRH). [1] By decreasing the frequency of release of GnRH,\u00a0medroxyprogesterone blunts the midcycle LH surge and prevents follicular maturation and ovulation. Medroxyprogesterone changes a proliferative endometrium to secretory endometrium, making implantation difficult. Finally,\u00a0medroxyprogesterone also impairs sperm migration into the uterus by increasing the viscosity of the cervical mucus. [1]"}
{"id": "article-24900_9", "title": "Medroxyprogesterone -- Mechanism of Action", "content": "In premenopausal women experiencing amenorrhea and irregular uterine bleeding,\u00a0medroxyprogesterone can be used to establish a normal menstrual cycle. Medroxyprogesterone also decreases endometrial growth in postmenopausal and menopausal women who receive estrogen therapy. Medroxyprogesterone acts on endometrial lesions and decreases endometrial-related pain in patients with endometriosis. [5]", "contents": "Medroxyprogesterone -- Mechanism of Action. In premenopausal women experiencing amenorrhea and irregular uterine bleeding,\u00a0medroxyprogesterone can be used to establish a normal menstrual cycle. Medroxyprogesterone also decreases endometrial growth in postmenopausal and menopausal women who receive estrogen therapy. Medroxyprogesterone acts on endometrial lesions and decreases endometrial-related pain in patients with endometriosis. [5]"}
{"id": "article-24900_10", "title": "Medroxyprogesterone -- Mechanism of Action -- Pharmacodynamics and Pharmacokinetics", "content": "Absorption Oral: Rapid IM: Slow Protein binding: 86% to 90% bound to albumin [5] Metabolism: Hepatic through hydroxylation and conjugation Bioavailability: 0.6% to 10% Half-Life Elimination [13] Oral: 12 to 17 hours IM: approximately 50 days SQ:\u00a0approximately\u00a043 days Time to Peak Oral: 2 to 7 hours [14] IM: 3 weeks to reach Cmax of 1\u00a0to 7 ng/mL SQ: 1 week to reach Cmax of\u00a00.953 ng/mL [5] Excretion: Urine as glucuronide conjugates with a small amount excreted as sulfates", "contents": "Medroxyprogesterone -- Mechanism of Action -- Pharmacodynamics and Pharmacokinetics. Absorption Oral: Rapid IM: Slow Protein binding: 86% to 90% bound to albumin [5] Metabolism: Hepatic through hydroxylation and conjugation Bioavailability: 0.6% to 10% Half-Life Elimination [13] Oral: 12 to 17 hours IM: approximately 50 days SQ:\u00a0approximately\u00a043 days Time to Peak Oral: 2 to 7 hours [14] IM: 3 weeks to reach Cmax of 1\u00a0to 7 ng/mL SQ: 1 week to reach Cmax of\u00a00.953 ng/mL [5] Excretion: Urine as glucuronide conjugates with a small amount excreted as sulfates"}
{"id": "article-24900_11", "title": "Medroxyprogesterone -- Administration", "content": "Specific dosing based on formulation and indication can be found in the drug's packaging information.", "contents": "Medroxyprogesterone -- Administration. Specific dosing based on formulation and indication can be found in the drug's packaging information."}
{"id": "article-24900_12", "title": "Medroxyprogesterone -- Administration -- Dose Formulations", "content": "IM\u00a0suspension: 150 mg/mL (1 mL)\u00a0injection vial or a prefilled syringe SQ\u00a0suspension: 104 mg/0.65 mL (0.65 mL) Tablet, oral: 2.5, 5, and 10 mg", "contents": "Medroxyprogesterone -- Administration -- Dose Formulations. IM\u00a0suspension: 150 mg/mL (1 mL)\u00a0injection vial or a prefilled syringe SQ\u00a0suspension: 104 mg/0.65 mL (0.65 mL) Tablet, oral: 2.5, 5, and 10 mg"}
{"id": "article-24900_13", "title": "Medroxyprogesterone -- Administration", "content": "Medroxyprogesterone injection inhibits ovulation for 14 weeks and must be administered every\u00a03 months (12 weeks) for continuous contraception. Administration can be either IM or SQ; severe adverse reactions can occur if administered IV.", "contents": "Medroxyprogesterone -- Administration. Medroxyprogesterone injection inhibits ovulation for 14 weeks and must be administered every\u00a03 months (12 weeks) for continuous contraception. Administration can be either IM or SQ; severe adverse reactions can occur if administered IV."}
{"id": "article-24900_14", "title": "Medroxyprogesterone -- Administration -- Oral Administration", "content": "Medroxyprogesterone tablets can be ingested sublingually and without regard to meals.", "contents": "Medroxyprogesterone -- Administration -- Oral Administration. Medroxyprogesterone tablets can be ingested sublingually and without regard to meals."}
{"id": "article-24900_15", "title": "Medroxyprogesterone -- Administration -- Injectable Administration", "content": "Inspect the product for discoloration and particulate matter before usage.", "contents": "Medroxyprogesterone -- Administration -- Injectable Administration. Inspect the product for discoloration and particulate matter before usage."}
{"id": "article-24900_16", "title": "Medroxyprogesterone -- Administration -- Intramuscular Administration\u00a0(Contraceptive Injection Suspension)", "content": "Administer the injection to the gluteal or deltoid region. Shake the suspension before injecting. Do not dilute the suspension before injecting. Do\u00a0not administer\u00a0the drug IV. Exclude the possibility of pregnancy, especially if 14 weeks have passed since the first dose.", "contents": "Medroxyprogesterone -- Administration -- Intramuscular Administration\u00a0(Contraceptive Injection Suspension). Administer the injection to the gluteal or deltoid region. Shake the suspension before injecting. Do not dilute the suspension before injecting. Do\u00a0not administer\u00a0the drug IV. Exclude the possibility of pregnancy, especially if 14 weeks have passed since the first dose."}
{"id": "article-24900_17", "title": "Medroxyprogesterone -- Administration -- Subcutaneous Administration\u00a0(Contraceptive Injection Suspension)", "content": "Inject a prefilled syringe into the anterior thigh or abdomen at a 45-degree angle. Pull the skin away from the body before injecting the drug. Shake the tube vigorously for 1 min before usage. Press the area lightly but do not rub\u00a0it\u00a0after the injection. Avoid giving this IM or IV. Administer within\u00a05 days of onset of menstrual bleeding. [15]", "contents": "Medroxyprogesterone -- Administration -- Subcutaneous Administration\u00a0(Contraceptive Injection Suspension). Inject a prefilled syringe into the anterior thigh or abdomen at a 45-degree angle. Pull the skin away from the body before injecting the drug. Shake the tube vigorously for 1 min before usage. Press the area lightly but do not rub\u00a0it\u00a0after the injection. Avoid giving this IM or IV. Administer within\u00a05 days of onset of menstrual bleeding. [15]"}
{"id": "article-24900_18", "title": "Medroxyprogesterone -- Administration -- Specific Patient Population", "content": "Hepatic impairment: Medroxyprogesterone should not be administered to\u00a0patients with significant liver impairment. If\u00a0the patient develops jaundice or liver function disturbances,\u00a0the drug should be stopped. [16]", "contents": "Medroxyprogesterone -- Administration -- Specific Patient Population. Hepatic impairment: Medroxyprogesterone should not be administered to\u00a0patients with significant liver impairment. If\u00a0the patient develops jaundice or liver function disturbances,\u00a0the drug should be stopped. [16]"}
{"id": "article-24900_19", "title": "Medroxyprogesterone -- Administration -- Specific Patient Population", "content": "Renal impairment: No dose adjustment recommendations are studied/provided in the manufacturer's prescribing label. Medroxyprogesterone can cause fluid retention, requiring caution in patients with preexisting kidney disease.", "contents": "Medroxyprogesterone -- Administration -- Specific Patient Population. Renal impairment: No dose adjustment recommendations are studied/provided in the manufacturer's prescribing label. Medroxyprogesterone can cause fluid retention, requiring caution in patients with preexisting kidney disease."}
{"id": "article-24900_20", "title": "Medroxyprogesterone -- Administration -- Specific Patient Population", "content": "Pregnancy considerations: Three percent\u00a0of the users experienced an unintended pregnancy, and efficacy was determined to be 99%. The drug is not recommended for women considering pregnancy soon as it may delay the return of fertility after discontinuation. Ectopic pregnancy has been reported with the use of medroxyprogesterone. [17]", "contents": "Medroxyprogesterone -- Administration -- Specific Patient Population. Pregnancy considerations: Three percent\u00a0of the users experienced an unintended pregnancy, and efficacy was determined to be 99%. The drug is not recommended for women considering pregnancy soon as it may delay the return of fertility after discontinuation. Ectopic pregnancy has been reported with the use of medroxyprogesterone. [17]"}
{"id": "article-24900_21", "title": "Medroxyprogesterone -- Administration -- Specific Patient Population", "content": "Breastfeeding considerations: Breastfeeding women should not use medroxyprogesterone until\u00a06 weeks postpartum in breastfeeding women, as infants are exposed to\u00a0medroxyprogesterone through breast milk. [18]", "contents": "Medroxyprogesterone -- Administration -- Specific Patient Population. Breastfeeding considerations: Breastfeeding women should not use medroxyprogesterone until\u00a06 weeks postpartum in breastfeeding women, as infants are exposed to\u00a0medroxyprogesterone through breast milk. [18]"}
{"id": "article-24900_22", "title": "Medroxyprogesterone -- Administration -- Specific Patient Population", "content": "Pediatric patients: Medroxyprogesterone use is not advised before menarche. Use is associated with a significant loss of bone mineral density, an important concern during adolescence and early adulthood. Older patients: Medroxyprogesterone has not been studied in postmenopausal women and is not indicated in this population.", "contents": "Medroxyprogesterone -- Administration -- Specific Patient Population. Pediatric patients: Medroxyprogesterone use is not advised before menarche. Use is associated with a significant loss of bone mineral density, an important concern during adolescence and early adulthood. Older patients: Medroxyprogesterone has not been studied in postmenopausal women and is not indicated in this population."}
{"id": "article-24900_23", "title": "Medroxyprogesterone -- Adverse Effects", "content": "Menstrual irregularities and weight gain are the most common adverse effects of medroxyprogesterone. [19] Regarding\u00a0weight gain, a\u00a0study reported that\u00a0medroxyprogesterone use increased by 1.61 in BMI and an average weight gain of 3.23 kg (7.11 lb). [20] Meanwhile,\u00a057.3% of the patients receiving medroxyprogesterone reported irregular menses during the first year. Irregular bleeding decreases to 30% after 24 months and 10% after 24 months. Fifty-five percent of women report amenorrhea after 12 months of therapy, increasing\u00a0to 68% after\u00a02 years.", "contents": "Medroxyprogesterone -- Adverse Effects. Menstrual irregularities and weight gain are the most common adverse effects of medroxyprogesterone. [19] Regarding\u00a0weight gain, a\u00a0study reported that\u00a0medroxyprogesterone use increased by 1.61 in BMI and an average weight gain of 3.23 kg (7.11 lb). [20] Meanwhile,\u00a057.3% of the patients receiving medroxyprogesterone reported irregular menses during the first year. Irregular bleeding decreases to 30% after 24 months and 10% after 24 months. Fifty-five percent of women report amenorrhea after 12 months of therapy, increasing\u00a0to 68% after\u00a02 years."}
{"id": "article-24900_24", "title": "Medroxyprogesterone -- Adverse Effects", "content": "The following adverse effects of medroxyprogesterone contraceptive injection have been noted: oligomenorrhea, delayed return to fertility, prolonged anovulation (temporary infertility), unexpected pregnancy, uterine hyperplasia, genitourinary infections, vaginal cysts, vaginal and uterine hemorrhage. In females who utilize medroxyprogesterone tablets without estrogen for hormone replacement therapy, bleeding, spotting, changes in menstrual flow, changes in cervical erosion, and changes in cervical secretions have been reported.", "contents": "Medroxyprogesterone -- Adverse Effects. The following adverse effects of medroxyprogesterone contraceptive injection have been noted: oligomenorrhea, delayed return to fertility, prolonged anovulation (temporary infertility), unexpected pregnancy, uterine hyperplasia, genitourinary infections, vaginal cysts, vaginal and uterine hemorrhage. In females who utilize medroxyprogesterone tablets without estrogen for hormone replacement therapy, bleeding, spotting, changes in menstrual flow, changes in cervical erosion, and changes in cervical secretions have been reported."}
{"id": "article-24900_25", "title": "Medroxyprogesterone -- Adverse Effects", "content": "Both genders reported experiencing changes in breast symptoms and sexual function. Females who used the medroxyprogesterone contraceptive injection reported breast pain (2.8%) and decreased libido (5.5%). Post-market reports with the injection usage determined other adverse effects such as breast lumps, changes in breast size, nipple bleeding, galactorrhea, dyspareunia, lactation suppression, and changes in libido. [21]", "contents": "Medroxyprogesterone -- Adverse Effects. Both genders reported experiencing changes in breast symptoms and sexual function. Females who used the medroxyprogesterone contraceptive injection reported breast pain (2.8%) and decreased libido (5.5%). Post-market reports with the injection usage determined other adverse effects such as breast lumps, changes in breast size, nipple bleeding, galactorrhea, dyspareunia, lactation suppression, and changes in libido. [21]"}
{"id": "article-24900_26", "title": "Medroxyprogesterone -- Adverse Effects", "content": "Females who only use medroxyprogesterone (without estrogen) for hormone replacement therapy reported mastodynia or mastalgia (breast pain), galactorrhea, and breast tenderness. Patients who used medroxyprogesterone in addition to estrogen for hormone replacement therapy reported breast tenderness, nipple breast discharge, fibrocystic breast changes, and breast cancer. In males, impotence and a decrease in testosterone levels by 25% were reported when they received medroxyprogesterone for palliative reasons.", "contents": "Medroxyprogesterone -- Adverse Effects. Females who only use medroxyprogesterone (without estrogen) for hormone replacement therapy reported mastodynia or mastalgia (breast pain), galactorrhea, and breast tenderness. Patients who used medroxyprogesterone in addition to estrogen for hormone replacement therapy reported breast tenderness, nipple breast discharge, fibrocystic breast changes, and breast cancer. In males, impotence and a decrease in testosterone levels by 25% were reported when they received medroxyprogesterone for palliative reasons."}
{"id": "article-24900_27", "title": "Medroxyprogesterone -- Adverse Effects", "content": "Angioedema, anaphylactic shock, and dermatologic reactions have been reported in users. Between 1% and 5% of the medroxyprogesterone users reported hot flashes and acne vulgaris. Alopecia was reported in 1.1% of patients who received contraceptive injections.", "contents": "Medroxyprogesterone -- Adverse Effects. Angioedema, anaphylactic shock, and dermatologic reactions have been reported in users. Between 1% and 5% of the medroxyprogesterone users reported hot flashes and acne vulgaris. Alopecia was reported in 1.1% of patients who received contraceptive injections."}
{"id": "article-24900_28", "title": "Medroxyprogesterone -- Adverse Effects", "content": "Postmarketing reports of contraceptive injection recipients indicated the following adverse effects: angioedema, dry skin, increased body odor, hyperhidrosis, axillary swelling, melasma, scleroderma, and urticaria. In women who used medroxyprogesterone in addition to estrogen for hormone replacement therapy, the following adverse effects occurred: chloasma or melasma after discontinuation, erythema multiforme, erythema nodosum, and alopecia. In addition, fixed drug eruption to medroxyprogesterone has been reported. [22]", "contents": "Medroxyprogesterone -- Adverse Effects. Postmarketing reports of contraceptive injection recipients indicated the following adverse effects: angioedema, dry skin, increased body odor, hyperhidrosis, axillary swelling, melasma, scleroderma, and urticaria. In women who used medroxyprogesterone in addition to estrogen for hormone replacement therapy, the following adverse effects occurred: chloasma or melasma after discontinuation, erythema multiforme, erythema nodosum, and alopecia. In addition, fixed drug eruption to medroxyprogesterone has been reported. [22]"}
{"id": "article-24900_29", "title": "Medroxyprogesterone -- Adverse Effects", "content": "Patients utilizing medroxyprogesterone contraceptive injections have reported dizziness (5.6%), insomnia (1% to 5%), nervousness (10.8%), depression (1% to 5%), anxiety or irritability (1% to 5%) and headaches (9% to 16.5%). If a patient experiences a headache or migraine with focal features consistent with cerebral ischemia, then discontinuation of medroxyprogesterone is recommended. [23]", "contents": "Medroxyprogesterone -- Adverse Effects. Patients utilizing medroxyprogesterone contraceptive injections have reported dizziness (5.6%), insomnia (1% to 5%), nervousness (10.8%), depression (1% to 5%), anxiety or irritability (1% to 5%) and headaches (9% to 16.5%). If a patient experiences a headache or migraine with focal features consistent with cerebral ischemia, then discontinuation of medroxyprogesterone is recommended. [23]"}
{"id": "article-24900_30", "title": "Medroxyprogesterone -- Adverse Effects", "content": "CNS adverse effects such as facial palsy, syncope, paralysis, and paresthesia have also occurred with contraceptive injection usage. In women utilizing medroxyprogesterone tablets along with estrogen, chorea and mood disturbances have been reported. Women utilizing the IM depot contraceptive injection reported gastrointestinal effects such as abdominal pain, nausea, and bloating. A rare case of splenic artery thrombosis has been reported. [24] Progestins stimulate the respiratory center and, as a result, during pregnancy and women's luteal phase of the menstrual cycle. Consequently,\u00a0medroxyprogesterone can cause hyperventilation resulting in\u00a0hypocapnia due to elevated levels of endogenous progestins. A study conducted in Thailand reported that pregnant women who took\u00a0medroxyprogesterone had infants with\u00a0polysyndactyly. The study also determined that the infants of these mothers were at an increased risk of having chromosomal abnormalities. [2] [25] [2]", "contents": "Medroxyprogesterone -- Adverse Effects. CNS adverse effects such as facial palsy, syncope, paralysis, and paresthesia have also occurred with contraceptive injection usage. In women utilizing medroxyprogesterone tablets along with estrogen, chorea and mood disturbances have been reported. Women utilizing the IM depot contraceptive injection reported gastrointestinal effects such as abdominal pain, nausea, and bloating. A rare case of splenic artery thrombosis has been reported. [24] Progestins stimulate the respiratory center and, as a result, during pregnancy and women's luteal phase of the menstrual cycle. Consequently,\u00a0medroxyprogesterone can cause hyperventilation resulting in\u00a0hypocapnia due to elevated levels of endogenous progestins. A study conducted in Thailand reported that pregnant women who took\u00a0medroxyprogesterone had infants with\u00a0polysyndactyly. The study also determined that the infants of these mothers were at an increased risk of having chromosomal abnormalities. [2] [25] [2]"}
{"id": "article-24900_31", "title": "Medroxyprogesterone -- Adverse Effects -- Drug-Drug Interactions", "content": "In vitro,\u00a0medroxyprogesterone is metabolized by CYP3A4. Therefore, inducers and inhibitors of CYP3A4 can affect the metabolism of medroxyprogesterone. [26] Drugs\u00a0that can reduce the\u00a0efficacy of medroxyprogesterone include barbiturates, carbamazepine,\u00a0oxcarbazepine, griseofulvin, bosentan, phenytoin, St. John\u2019s wort, rifampin, and topiramate. [27] [28] [29] Product labeling\u00a0specifies\u00a0that significant\u00a0changes\u00a0(increase or decrease) in the plasma\u00a0concentration of progestin have been\u00a0marked\u00a0with the coadministration of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTIs) with medroxyprogesterone. Use with caution. [30] [31] [32]", "contents": "Medroxyprogesterone -- Adverse Effects -- Drug-Drug Interactions. In vitro,\u00a0medroxyprogesterone is metabolized by CYP3A4. Therefore, inducers and inhibitors of CYP3A4 can affect the metabolism of medroxyprogesterone. [26] Drugs\u00a0that can reduce the\u00a0efficacy of medroxyprogesterone include barbiturates, carbamazepine,\u00a0oxcarbazepine, griseofulvin, bosentan, phenytoin, St. John\u2019s wort, rifampin, and topiramate. [27] [28] [29] Product labeling\u00a0specifies\u00a0that significant\u00a0changes\u00a0(increase or decrease) in the plasma\u00a0concentration of progestin have been\u00a0marked\u00a0with the coadministration of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTIs) with medroxyprogesterone. Use with caution. [30] [31] [32]"}
{"id": "article-24900_32", "title": "Medroxyprogesterone -- Adverse Effects -- Drug-Laboratory\u00a0Interference", "content": "Gonadotropin levels\u00a0are reduced, and sex hormone-binding globulin is increased. [33] Administration of\u00a0medroxyprogesterone can increase\u00a0total T4, total T3, and thyroid-binding globulin levels; T3 uptake is also altered. [34]", "contents": "Medroxyprogesterone -- Adverse Effects -- Drug-Laboratory\u00a0Interference. Gonadotropin levels\u00a0are reduced, and sex hormone-binding globulin is increased. [33] Administration of\u00a0medroxyprogesterone can increase\u00a0total T4, total T3, and thyroid-binding globulin levels; T3 uptake is also altered. [34]"}
{"id": "article-24900_33", "title": "Medroxyprogesterone -- Contraindications", "content": "Medroxyprogesterone is contraindicated in patients with known hypersensitivity to the drug or its excipients. Cases of angioedema and anaphylactic reaction have occurred in patients utilizing medroxyprogesterone. [35] Both forms of the drug (oral and injection) are contraindicated in patients with pre-existing breast cancer. In patients with a history of breast cancer, renal cancer, endometrial cancer, or a family history of breast cancer, medroxyprogesterone is contraindicated. Medroxyprogesterone injection has shown a slightly increased risk of developing breast cancer. [36] [37] [38] Medroxyprogesterone is contraindicated in patients with undiagnosed vaginal bleeding.", "contents": "Medroxyprogesterone -- Contraindications. Medroxyprogesterone is contraindicated in patients with known hypersensitivity to the drug or its excipients. Cases of angioedema and anaphylactic reaction have occurred in patients utilizing medroxyprogesterone. [35] Both forms of the drug (oral and injection) are contraindicated in patients with pre-existing breast cancer. In patients with a history of breast cancer, renal cancer, endometrial cancer, or a family history of breast cancer, medroxyprogesterone is contraindicated. Medroxyprogesterone injection has shown a slightly increased risk of developing breast cancer. [36] [37] [38] Medroxyprogesterone is contraindicated in patients with undiagnosed vaginal bleeding."}
{"id": "article-24900_34", "title": "Medroxyprogesterone -- Contraindications", "content": "Medroxyprogesterone use requires caution in patients with diabetes. Hormonal contraceptives have been known to alter insulin sensitivity and, as a result, glucose tolerance. Medroxyprogesterone injections are contraindicated in patients with a history of arterial or venous thromboembolic (VTE) diseases or with an increased risk for stroke, heart disease, and arterial vascular disease. [23] Hormonal contraceptives can cause fluid retention and, as a result, should be used with caution in patients with asthma, congestive heart failure, and nephrotic syndrome.", "contents": "Medroxyprogesterone -- Contraindications. Medroxyprogesterone use requires caution in patients with diabetes. Hormonal contraceptives have been known to alter insulin sensitivity and, as a result, glucose tolerance. Medroxyprogesterone injections are contraindicated in patients with a history of arterial or venous thromboembolic (VTE) diseases or with an increased risk for stroke, heart disease, and arterial vascular disease. [23] Hormonal contraceptives can cause fluid retention and, as a result, should be used with caution in patients with asthma, congestive heart failure, and nephrotic syndrome."}
{"id": "article-24900_35", "title": "Medroxyprogesterone -- Contraindications", "content": "When using medroxyprogesterone in postmenopausal women along with estrogen therapy, it is associated with cardiovascular and thromboembolic risks. [2] Medroxyprogesterone use requires caution in women with hypertension, and blood pressure\u00a0requires regular monitoring. Though estrogen-progestin combinations are known to alter serum lipid levels, it is essential to be cautious about medroxyprogesterone, a progestin-only contraceptive. Therefore,\u00a0clinicians should check HDL and LDL regularly in patients. Although no congenital disabilities have been noted in patients exposed to medroxyprogesterone, it is contraindicated in pregnancy or suspected pregnancy.", "contents": "Medroxyprogesterone -- Contraindications. When using medroxyprogesterone in postmenopausal women along with estrogen therapy, it is associated with cardiovascular and thromboembolic risks. [2] Medroxyprogesterone use requires caution in women with hypertension, and blood pressure\u00a0requires regular monitoring. Though estrogen-progestin combinations are known to alter serum lipid levels, it is essential to be cautious about medroxyprogesterone, a progestin-only contraceptive. Therefore,\u00a0clinicians should check HDL and LDL regularly in patients. Although no congenital disabilities have been noted in patients exposed to medroxyprogesterone, it is contraindicated in pregnancy or suspected pregnancy."}
{"id": "article-24900_36", "title": "Medroxyprogesterone -- Contraindications", "content": "The suspension injections can induce temporary infertility at higher concentrations, and patients experience delays in returning to baseline after\u00a0ceasing treatment. Medroxyprogesterone tablets are also contraindicated in patients with incomplete abortions. In women with hepatic dysfunction or hepatic diseases, medroxyprogesterone usage is contraindicated. Use should be discontinued in women who experience jaundice or disturbances with their liver function. In women with a history of major depression, migraine, or seizure disorder, medroxyprogesterone should be used with caution, as progestin can exacerbate these conditions.\u00a0 Clinicians\u00a0should counsel patients that using medroxyprogesterone does not protect against human immunodeficiency virus (HIV) infection or other sexually transmitted diseases. [39]", "contents": "Medroxyprogesterone -- Contraindications. The suspension injections can induce temporary infertility at higher concentrations, and patients experience delays in returning to baseline after\u00a0ceasing treatment. Medroxyprogesterone tablets are also contraindicated in patients with incomplete abortions. In women with hepatic dysfunction or hepatic diseases, medroxyprogesterone usage is contraindicated. Use should be discontinued in women who experience jaundice or disturbances with their liver function. In women with a history of major depression, migraine, or seizure disorder, medroxyprogesterone should be used with caution, as progestin can exacerbate these conditions.\u00a0 Clinicians\u00a0should counsel patients that using medroxyprogesterone does not protect against human immunodeficiency virus (HIV) infection or other sexually transmitted diseases. [39]"}
{"id": "article-24900_37", "title": "Medroxyprogesterone -- Contraindications -- Box Warnings", "content": "Estrogens and progestins should not be used\u00a0for cardiovascular disease prophylaxis. An increased risk of myocardial infarction, pulmonary embolism,\u00a0deep vein thrombosis, and stroke in postmenopausal women (50\u00a0to 79 years) is seen with\u00a0prolonged treatment when\u00a0medroxyprogesterone is combined with\u00a0conjugated estrogens. [40] [41] MPA\u00a0depot injection can\u00a0decrease bone mineral density, possibly irreversible in postmenopausal women. Calcium and vitamin D\u00a0supplementation are recommended. [42] MPA\u00a0injection\u00a0is not advised as a long-term (ie,\u00a0older than\u00a02 years) birth control; and should be utilized only when other birth control options are deemed inadequate. A\u00a0risk of dementia in postmenopausal women 65 years and older during\u00a04 years of daily treatment with conjugated estrogen\u00a0plus medroxyprogesterone is evident. [43] [44]", "contents": "Medroxyprogesterone -- Contraindications -- Box Warnings. Estrogens and progestins should not be used\u00a0for cardiovascular disease prophylaxis. An increased risk of myocardial infarction, pulmonary embolism,\u00a0deep vein thrombosis, and stroke in postmenopausal women (50\u00a0to 79 years) is seen with\u00a0prolonged treatment when\u00a0medroxyprogesterone is combined with\u00a0conjugated estrogens. [40] [41] MPA\u00a0depot injection can\u00a0decrease bone mineral density, possibly irreversible in postmenopausal women. Calcium and vitamin D\u00a0supplementation are recommended. [42] MPA\u00a0injection\u00a0is not advised as a long-term (ie,\u00a0older than\u00a02 years) birth control; and should be utilized only when other birth control options are deemed inadequate. A\u00a0risk of dementia in postmenopausal women 65 years and older during\u00a04 years of daily treatment with conjugated estrogen\u00a0plus medroxyprogesterone is evident. [43] [44]"}
{"id": "article-24900_38", "title": "Medroxyprogesterone -- Monitoring", "content": "Patients require evaluation regarding their pregnancy status before starting therapy and if 14 weeks have passed since the last injection. Also, weight and bone mineral density should be evaluated\u00a0regularly; consider bone mineral density in female patients with a strong history of breast cancer and the possibility of developing endometrial cancer, especially with long-term medroxyprogesterone use. Endometrial sampling is recommended every 3\u00a0to 5 months to monitor continually for endometrial hyperplasia. [45] [7]", "contents": "Medroxyprogesterone -- Monitoring. Patients require evaluation regarding their pregnancy status before starting therapy and if 14 weeks have passed since the last injection. Also, weight and bone mineral density should be evaluated\u00a0regularly; consider bone mineral density in female patients with a strong history of breast cancer and the possibility of developing endometrial cancer, especially with long-term medroxyprogesterone use. Endometrial sampling is recommended every 3\u00a0to 5 months to monitor continually for endometrial hyperplasia. [45] [7]"}
{"id": "article-24900_39", "title": "Medroxyprogesterone -- Monitoring", "content": "For menopausal patients currently using combination hormonal therapy, the risk for breast cancer and cardiovascular disease\u00a0requires assessment.\u00a0After initiating\u00a0medroxyprogesterone therapy,\u00a0the healthcare team must assess blood pressure and any unscheduled bleeding of greater than\u00a06 months duration to evaluate for endometrial pathology. Additionally, patients should be administered breast exams and pelvic exams, depending on their age. These parameters should be followed even more closely for patients with diabetes, obesity, or a family history of endometrial cancer. Serum triglycerides should be monitored closely and checked\u00a02 weeks after initiating therapy in patients with elevated triglycerides (>200 mg/dL). For patients currently\u00a0receiving thyroid replacements, TSH levels must also be monitored 6\u00a0to 12 weeks after starting on oral medroxyprogesterone tablets. [9] If patients are currently prescribed\u00a0medroxyprogesterone for paraphilia/hypersexuality, liver function tests (LFTs), complete blood count (CBC), serum testosterone, LH, FSH, and glucose require regular monitoring. Also, consider an annual bone scan if serum testosterone markedly decreases. [46] [47]", "contents": "Medroxyprogesterone -- Monitoring. For menopausal patients currently using combination hormonal therapy, the risk for breast cancer and cardiovascular disease\u00a0requires assessment.\u00a0After initiating\u00a0medroxyprogesterone therapy,\u00a0the healthcare team must assess blood pressure and any unscheduled bleeding of greater than\u00a06 months duration to evaluate for endometrial pathology. Additionally, patients should be administered breast exams and pelvic exams, depending on their age. These parameters should be followed even more closely for patients with diabetes, obesity, or a family history of endometrial cancer. Serum triglycerides should be monitored closely and checked\u00a02 weeks after initiating therapy in patients with elevated triglycerides (>200 mg/dL). For patients currently\u00a0receiving thyroid replacements, TSH levels must also be monitored 6\u00a0to 12 weeks after starting on oral medroxyprogesterone tablets. [9] If patients are currently prescribed\u00a0medroxyprogesterone for paraphilia/hypersexuality, liver function tests (LFTs), complete blood count (CBC), serum testosterone, LH, FSH, and glucose require regular monitoring. Also, consider an annual bone scan if serum testosterone markedly decreases. [46] [47]"}
{"id": "article-24900_40", "title": "Medroxyprogesterone -- Toxicity", "content": "Patients experiencing\u00a0medroxyprogesterone\u00a0overdose may experience nausea, vomiting, seizures, trouble breathing, and altered mental status. Treatment is primarily supportive.", "contents": "Medroxyprogesterone -- Toxicity. Patients experiencing\u00a0medroxyprogesterone\u00a0overdose may experience nausea, vomiting, seizures, trouble breathing, and altered mental status. Treatment is primarily supportive."}
{"id": "article-24900_41", "title": "Medroxyprogesterone -- Enhancing Healthcare Team Outcomes", "content": "Medroxyprogesterone can be administered via injection or oral tablet. Administering\u00a0medroxyprogesterone\u00a0requires communication between all interprofessional healthcare team members. Communication includes providing detailed instructions on different ways of administering IM and SQ injections and avoiding IV administration altogether. Additionally, clinicians and pharmacists must work together to determine appropriate forms of medroxyprogesterone, given the patient's symptoms and diagnosis. This level of collaboration can assist in avoiding adverse effects on patients and the potential development of invasive cancers and involves the entire interprofessional team.\u00a0Pharmacists should\u00a0verify\u00a0the prescription before dispensing, as\u00a0medroxyprogesterone\u00a0can be confused with methyltestosterone and methylprednisolone. [48] They should also verify dosing and administration techniques, perform medication reconciliation, and offer patient counseling regarding their prescription.", "contents": "Medroxyprogesterone -- Enhancing Healthcare Team Outcomes. Medroxyprogesterone can be administered via injection or oral tablet. Administering\u00a0medroxyprogesterone\u00a0requires communication between all interprofessional healthcare team members. Communication includes providing detailed instructions on different ways of administering IM and SQ injections and avoiding IV administration altogether. Additionally, clinicians and pharmacists must work together to determine appropriate forms of medroxyprogesterone, given the patient's symptoms and diagnosis. This level of collaboration can assist in avoiding adverse effects on patients and the potential development of invasive cancers and involves the entire interprofessional team.\u00a0Pharmacists should\u00a0verify\u00a0the prescription before dispensing, as\u00a0medroxyprogesterone\u00a0can be confused with methyltestosterone and methylprednisolone. [48] They should also verify dosing and administration techniques, perform medication reconciliation, and offer patient counseling regarding their prescription."}
{"id": "article-24900_42", "title": "Medroxyprogesterone -- Enhancing Healthcare Team Outcomes", "content": "Nursing staff\u00a0and other healthcare team members need training in treating contraceptive overdose and the symptoms that could point in the direction of overdose. Nurses and other clinicians in the emergency department (ED) must work together to obtain drug levels in the blood and treat them to prevent any immediate adverse effects resulting from the overdose. To treat any long-term symptoms of the overdose, the healthcare team in the ED should consult with a toxicologist and pharmacist to provide evidence-based medical intervention. [49]", "contents": "Medroxyprogesterone -- Enhancing Healthcare Team Outcomes. Nursing staff\u00a0and other healthcare team members need training in treating contraceptive overdose and the symptoms that could point in the direction of overdose. Nurses and other clinicians in the emergency department (ED) must work together to obtain drug levels in the blood and treat them to prevent any immediate adverse effects resulting from the overdose. To treat any long-term symptoms of the overdose, the healthcare team in the ED should consult with a toxicologist and pharmacist to provide evidence-based medical intervention. [49]"}
{"id": "article-24900_43", "title": "Medroxyprogesterone -- Enhancing Healthcare Team Outcomes", "content": "Medical staff should be prepared to inform patients about long-term usage risks and adverse effects. The healthcare team must work together to educate women with accurate information and, in the process,\u00a0counter the inaccurate information spread through magazines and other patient-friendly lay platforms. [19] Patients should\u00a0obtain counsel regarding the risk of osteoporosis and be screened regularly for breast cancer. They should also be informed about the likely menstrual disturbances and their length. [50] The interprofessional efforts of primary care clinicians, gynecologists, advanced practice practitioners, pharmacists, nursing staff, and pharmacists can improve therapeutic outcomes while minimizing adverse patient events when using medroxyprogesterone.", "contents": "Medroxyprogesterone -- Enhancing Healthcare Team Outcomes. Medical staff should be prepared to inform patients about long-term usage risks and adverse effects. The healthcare team must work together to educate women with accurate information and, in the process,\u00a0counter the inaccurate information spread through magazines and other patient-friendly lay platforms. [19] Patients should\u00a0obtain counsel regarding the risk of osteoporosis and be screened regularly for breast cancer. They should also be informed about the likely menstrual disturbances and their length. [50] The interprofessional efforts of primary care clinicians, gynecologists, advanced practice practitioners, pharmacists, nursing staff, and pharmacists can improve therapeutic outcomes while minimizing adverse patient events when using medroxyprogesterone."}
{"id": "article-24900_44", "title": "Medroxyprogesterone -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Medroxyprogesterone -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}